查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1920864

藥品合約生產市場（第五版）：趨勢與預測至 2035 年 - 按產品類型、原料藥類型、原料藥濃度、成品製劑、劑型、口服固體製劑、最終用戶、地區和主要公司劃分

Pharmaceutical Contract Manufacturing Market (5th Edition): Trends and Forecast Till 2035 - Distribution by Type of Product Manufactured, Type of API, API Potency, FDF, Dosage Form, Oral Solid, End User, Geographical Regions and Key Players
出版日期: | 出版商: Roots Analysis | 英文 545 Pages | 商品交期: 最快1-2個工作天內

價格

藥品合約生產市場：概論

根據 Roots Analysis 的一項研究，預計到 2035 年，藥品合約生產市場將以 4.5% 的複合年增長率增長，從目前的 1003 億美元增長至 1554 億美元。

藥品合約生產市場：成長與趨勢

合約生產是指將特定的研發和/或生產活動外包給外部服務提供者。這意味著一家公司使用另一家公司的標籤或品牌來開發產品。製藥公司最常外包的活動包括製劑設計、劑型開發、臨床/商業生產、包裝和物流。

值得注意的是，現代候選藥物的研發管線日益複雜，需要專門的設施、設備和操作知識。慢性病患者人數也在顯著增加，對創新藥物的需求持續成長。為了滿足這一不斷增長的需求，許多中小企業以及一些大型製藥公司已開始將生產活動外包給合約服務提供者。技術發展和市場對創新療法的需求也在推動藥物研發的持續發展。

值得注意的是，合約生產組織 (CMO) 正在透過採用客製化療法、連續生產流程和數位健康整合技術來適應新的趨勢。透過擁抱創新、永續發展和團隊合作，製藥 CMO 正在對醫療保健產業產生重大影響，預計未來幾年將實現顯著成長。

成長驅動因素：市場擴張的策略基礎

對新型療法（例如生物製藥、單株抗體、抗體藥物偶聯物 (ADC) 和 GLP-1 藥物）的需求不斷增長，推動了製藥企業將生產外包給具備先進能力的專業合約生產組織 (CMO)。此外，關鍵生物製藥的專利到期以及品牌藥定價挑戰迫使製藥公司尋求更具成本效益的合約生產策略。同時，慢性病發病率的上升和對新藥的需求增加，也使得製藥公司更加依賴 CMO 的可擴展生產能力和快速上市時間。

市場挑戰：發展面臨的重大障礙

製藥合約生產市場面臨許多成長障礙，包括來自 FDA 和 EMA 等監管機構的嚴格監管要求以及不斷上漲的生產技術成本。這些障礙給合約製造商帶來了高昂的合規成本。此外，全球貿易不穩定正在擾亂活性藥物成分 (API) 和原料的供應鏈，加劇美國和歐洲的價格壓力，使成本管理面臨更大挑戰。

醫藥合約生產市場：關鍵洞察

本報告深入分析了醫藥合約生產市場的現狀，並指出了該行業的潛在成長機會。主要發現包括：

  • 在當前市場格局中，全球約有 510 家公司聲稱提供醫藥合約生產服務，其中 50% 的公司總部位於亞太地區。
Pharmaceutical Contract Manufacturing Market-IMG1
  • 大多數製藥合約製造商（約佔90%）提供成品劑型製備服務，超過75%的公司提供填充、包裝和貼標服務。
  • 併購使公司能夠將自身打造為一站式服務商，並在不斷變化的市場環境中建立競爭優勢。
醫藥合約生產市場-IMG2
  • 為了滿足日益增長的小分子藥物需求，合約生產組織（CMO）已投入大量資金擴大其現有生產和技術能力。近年來，這一趨勢在歐洲尤為明顯。
  • 全球醫藥合約生產能力均勻分佈於世界各地的不同工廠。特別是大型和超大型公司，佔了超過85%的總產能。
  • 隨著企業尋求降低建立和維護自有生產設施的高額資本投資和營運成本，對醫藥合約生產的需求預計將顯著增長。
  • 北美目前佔醫藥合約生產市場的大部分佔有率。這得歸功於該地區先進的醫療基礎設施，使企業能夠進行廣泛的研究。
  • 由於口服固體製劑具有成本效益高、給藥方便、患者依從性高等優點，預計今年該細分市場將佔整體市場的大部分佔有率。
Pharmaceutical Contract Manufacturing Market-IMG3
  • 預計北美將佔整體藥品合約生產市場的大部分佔有率，而這一趨勢預計將持續下去。
  • 預計美國藥品合約生產市場將以4.3%的複合年增長率成長。這主要是由於對小分子化合物的需求不斷增長，從而推動了對先進生產能力的需求。
  • 由於對小分子藥物的需求不斷增長，以及併購和業務擴張的增加，預計未來幾年醫藥合約生產（CMO）市場將經歷顯著增長。

醫藥合約生產市場

市場規模與機會分析依下列參數分類：

依產品類型

  • 活性藥物成分 (API) 與中間體
  • 成品藥物遞送 (FDF)

按 API 類型

  • 原廠藥
  • 仿製藥

按 API 效價

  • 低效價 API
  • 高效價 API

成品藥物遞送 (FDF) 類型

  • 原廠 FDF
  • 學名藥 FDF

按劑型

  • 口服固體劑型
  • 液體劑型劑量
  • 乳劑
  • 其他劑型

依口服固體劑型分類

  • 片劑
  • 膠囊
  • 其他

依包裝類型分類

  • 瓶裝
  • 泡罩包裝
  • 西林瓶
  • 預灌封注射器
  • 卡尺式註射器
  • 安瓿瓶
  • 口服液瓶裝
  • 其他

依企業規模分類

  • 臨床
  • 商業

依最終使用者分類

  • 小型
  • 中型
  • 大型和超大型企業

按區域

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 比利時
  • 瑞士
  • 英國
  • 德國
  • 愛爾蘭
  • 荷蘭
  • 義大利
  • 法國
  • 瑞典
  • 歐洲其他地區

亞太地區及世界其他地區

  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太地區其他地區及世界其他地區

醫藥合約生產市場：主要細分市場

低效價原料藥生產引領醫藥合約生產市場

目前，低效價原料藥佔整個市場的85%。這主要歸功於其大規模生產和可擴展的生產方法。此外，這些原料藥被製藥公司用於治療各種疾病，例如糖尿病和傳染病。這種廣泛的應用促使了全球持續的高需求。特別是，高活性原料藥市場預計將以更快的速度成長。這種增長是由對標靶治療和精準醫療日益增長的需求所驅動的，這些療法即使在極低劑量下也因其強大的治療效果而被證明非常有效。

口服固體製劑在製藥合約生產市場中佔主導地位，推動了龐大的需求。

口服固體製劑生產約佔製藥合約生產市場總收入的55%。這歸功於其低成本、患者便利性和大規模生產的效率。展望未來，預計在整個預測期內，液體製劑類別將在製藥合約生產市場中呈現更大的成長。

北美在製藥合約生產市場中處於領先地位，約佔總收入的45%。北美高度發展的製藥業、健全的監管體係以及眾多成熟的全球製藥公司的存在，正在推動該地區對製藥合約製造商的需求。

醫藥合約生產市場代表性公司

  • Albemarle
  • Aspen Pharmacare
  • Bausch Health Sciences
  • Catalent
  • Delpharm
  • Eurofins Scientific
  • Evonik Industries
  • Fareva
  • Fresenius Kabi
  • Intas Pharmaceuticals
  • Lonza
  • Micro Labs
  • Nipro Patch
  • Patheon
  • PiSA Farmaceutica
  • Recipharm
  • Sandoz
  • West Pharmaceutical Services
  • Wockhardt
  • WuXi AppTec

醫藥合約生產市場：研究範圍

  • 市場規模和機會分析：本報告對醫藥合約生產市場進行了詳細分析，重點關注針對關鍵市場細分領域。涵蓋內容包括：[A] 產品類型，[B] 原料藥類型，[C] 原料藥效價，[D] 成品製劑類型，[E] 劑型，[F] 口服固體製劑類型，[G] 提供的包裝類型，[H] 公司規模，[I] 最終用戶，以及 [J] 地理區域。
  • 市場概況：本報告詳細概述了目前為小分子藥物提供合約生產服務的公司現狀。內容包括：[A] 成立年份，[B] 生產設施所在地，[C] 提供的服務類型，[D] 生產的藥品類型，[E] 公司規模，[F] 提供的服務類型，[G] 生產的成品製劑類型，以及 [H] 提供的包裝類型。
  • 公司簡介：本報告基於以下五個方面，對北美、歐洲和亞太地區勝肽類藥物生產市場的主要參與者進行了深入分析：[A] 成立年份，[B] 總部所在地，[C] 產品組合，[D] 近期發展，以及 [E] 未來展望。
  • 內部生產與外包標準：本報告對藥物研發企業在決定是自行生產還是使用合約生產組織 (CMO) 的服務時應考慮的各種因素進行了定性分析。
  • 併購：本報告基於多個相關參數，對該領域的各種併購案例進行了深入分析，包括：[A] 協議年份，[B] 協議類型，[C] 地區，[D] 最活躍的參與者（按協議數量計），所有權變更矩陣，以及收購協議的關鍵價值驅動因素。
  • 近期擴張趨勢：本報告詳細分析了醫藥合約生產領域的擴張案例。分析基於相關參數，例如擴張時機、擴張狀態、擴張類型、設施位置、投資金額、生產的藥品類型、提供的服務類型以及主要參與者。
  • 區域產能分析：對北美、歐洲、亞太地區和世界其他地區（ROW）的藥品合約生產設施的區域產能進行詳細分析。
  • 產能分析：基於公開資訊和利害關係人報告的數據，該分析估算了藥品生產的總裝置產能。它根據[A]製造商規模（小型、中型、大型和超大型）和[B]地區（北美、歐洲、亞太地區和世界其他地區）確定了可用產能的分佈。
  • 需求分析：基於多個相關參數（例如[A]營運規模、[B]原料藥類型、[C]原料藥效價和[D]地理區域）對小分子藥物的年度需求進行合理估算。
  • 市場影響分析：對可能影響全球醫藥合約生產市場成長的因素進行詳細分析。報告也重點識別和分析了[A]關鍵驅動因素、[B]潛在限制因素、[C]新興機會和[D]現有挑戰。

目錄

第一章：引言

第二章：研究方法

第三章：市場動態

第四章：宏觀經濟指標

第五章：摘要整理

第六章：引言

  • 章節概述
  • 第三方製造商類型
  • 藥品合約生產概述
  • 藥品合約生產的演變
  • 製藥業外包的需求
  • 藥品合約生產產業的最新趨勢
  • 合約生產機構提供的服務
  • 選擇合約生產機構時的重要考量因素
  • 風險與挑戰與藥品生產外包相關的
  • 未來展望

第七章 藥品合約生產組織：監管環境

  • 章節概述
  • 北美監管環境
  • 歐洲監管環境
  • 亞太地區及世界其他地區監管環境
  • 依監理審批狀態分析藥品合約生產組織
  • 監理環境：區域基準分析

第八章 藥品合約生產組織：市場環境

  • 章節概述
  • 藥品合約生產組織：市場環境

第九章 公司簡介 - 主要參與者

  • 章節概述
  • 北美藥品合約生產組織美國
    • 雅寶
    • 鮑什健康服務
    • 康泰倫特
    • 帕森
    • PiSA Farmaceutica
    • 西藥服務
  • 歐洲合約製造組織
    • 德爾法姆
    • 歐陸科學
    • 贏創工業
    • 法雷瓦
    • 費森尤斯‧卡比
    • 龍沙
    • Recipharm
    • 山德士
  • 亞太地區及其他地區的合約製造組織
    • 阿斯彭製藥
    • Intas 藥廠
    • 微實驗室
    • Nipro Patch
    • 藥明康德
    • 沃克哈特

第十章 自製或外購決策架構

  • 章節概述
  • 假設和關鍵參數
  • 藥品合約製造商：自製或外購決策
  • 結論

第十一章：併購

  • 章節概述
  • 併購類型
  • 藥品合約生產組織：併購

第十二章：近期擴張

  • 章節概述
  • 擴張型
  • 醫藥合約生產組織：近期擴張

第13章：區域產能分析

  • 章節概述
  • 假設和關鍵參數
  • 醫藥合約生產設施概述

第14章：產能分析

第15章：需求分析

第16章：市場影響分析：驅動因素、限制因素、機會與挑戰

第17章：全球醫藥合約生產市場

第18章：醫藥合約生產市場（依產品類型劃分）

第19章：醫藥合約生產市場（依原始藥物類型劃分）

第20章：藥品合約生產市場（依原始藥效價劃分）

第21章：藥品合約生產市場（依成品製劑類型劃分）

第22章：藥品合約生產市場（以劑型劃分）

第23章：藥品合約生產市場（依口服固體製劑劃分）

第24章：藥品合約生產市場（依包裝規格劃分）

第25章：藥品合約生產市場（依企業規模劃分）

第26章：藥品合約生產市場（依最終用戶劃分）

第27章：藥品合約生產市場（依地區劃分）

第28章：藥品合約生產市場：北美

第29章：藥品合約生產市場：歐洲

第30章：醫藥合約生產市場：亞太地區

第31章：醫藥合約生產市場：世界其他地區

第32章：醫藥合約生產市場（依主要公司劃分）

第33章：個案研究：小分子藥物與大分子藥物/療法

第34章：結論

第35章：高階主管洞察

第36章：附錄一：表格資料

第37章：附錄二：公司與機構列表

Product Code: RA100285

Pharmaceutical Contract Manufacturing Market: Overview

As per Roots Analysis, the pharmaceutical contract manufacturing market is estimated to grow from USD 100.3 billion in the current year to USD 155.4 billion by 2035, at a CAGR of 4.5% during the forecast period, till 2035.

Pharmaceutical Contract Manufacturing Market: Growth and Trends

Contract manufacturing involves outsourcing specific development and / or production tasks to an external service provider. This entails the development of products by one firm, using the label or brand of a different firm. The most frequently outsourced tasks by pharmaceutical companies encompass formulation design, dosage form development, clinical / commercial manufacturing, packaging, and logistics.

Interestingly, the contemporary pipeline of drug candidates is becoming increasingly intricate, necessitating specialized facilities, equipment, and operational knowledge. The number of individuals affected by chronic illnesses has also risen considerably, leading to a continuous need for innovative medications. To address this increasing demand, various smaller companies and some large pharmaceutical firms have started outsourcing their production activities to contract service providers. Technological developments and market need for innovative treatments have also persisted in their development.

Notably, CMOs are adapting to new trends by incorporating customized therapies, ongoing manufacturing methods, and techniques for digital health integration. Through adopting innovation, sustainability, and teamwork, pharmaceutical CMOs will greatly impact the healthcare field and witness notable growth in the coming years.

Growth Drivers: Strategic Enablers of Market Expansion

Increasing demand for biologics, monoclonal antibodies, and novel therapies such as ADCs and GLP-1 medications drive outsourcing to expert CMOs with enhanced capabilities. Further, expiring patents of major biologics and pricing challenges for innovator medications necessitates pharmaceutical firms to pursue cost-effective contract manufacturing strategies. In addition, rising rates of chronic illnesses and the demand for new medications boost dependence on CMOs for scalable manufacturing and quicker time-to-market.

Market Challenges: Critical Barriers Impeding Progress

The pharmaceutical contract manufacturing market faces significant hurdles that hinder its growth including stringent regulatory compliance from regulatory bodies like the FDA and EMA, coupled with rising costs of production technologies. These hurdles burden CMOs with high compliance expenses. Further, global trade instability disrupts supply chains for APIs and raw materials, while pricing pressures in the US and Europe intensify cost management issues.

Pharmaceutical Contract Manufacturing Market: Key Insights

The report delves into the current state of the pharmaceutical contract manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • The current market landscape features the presence of close to 510 players that claim to offer contract manufacturing services for pharmaceuticals across the world; 50% of these are headquartered in Asia-Pacific.
Pharmaceutical Contract Manufacturing Market - IMG1
  • Majority (~90%) of the pharmaceutical contract manufacturers offer services for producing finished dose formulations; further, >75% players offer services for fill finish / packaging and labeling.
  • M&As allow companies to establish themselves as one-stop shops and build a competitive edge in the steadily evolving market landscape.
Pharmaceutical Contract Manufacturing Market - IMG2
  • In order to meet the rising demand for small molecules, CMOs have made significant investments in expanding their existing capacities and capabilities; in the recent past, this trend was most pronounced in Europe.
  • The global pharmaceutical contract manufacturing capacity is well distributed across different facilities worldwide; notably, large and very large players account for more than 85% of the total capacity.
  • In order to reduce high capital investments and operational costs associated with setting up and maintaining an in-house production facility, the demand for pharmaceutical contract manufacturing is anticipated to rise significantly.
  • Currently, majority of the pharmaceutical contract manufacturing market share is captured by North America; this can be attributed to the advanced healthcare infrastructure, enabling players to conduct extensive research.
  • The oral solids sub-segment is estimated to capture majority of the overall market share in the current year, owing to their cost-efficiency, ease of administration and high patient compliance.
Pharmaceutical Contract Manufacturing Market - IMG3
  • North America is expected to capture a significant market share of the overall pharmaceutical contract manufacturing market; this trend is unlikely to change in the future.
  • Pharmaceutical contract manufacturing market in the US is expected to grow at CAGR of 4.3%; this is due to the increasing demand for small molecules, consequently fueling the need for advanced manufacturing capabilities.
  • Given the rising demand for small molecules, along with the rise in mergers and acquisitions, and expansion activity, the pharmaceutical CMO market is likely to experience substantial growth in the coming years.

Pharmaceutical Contract Manufacturing Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Product Manufactured

  • API & Intermediates
  • FDF

By Type of API

  • Originator API
  • Generic API

By API Potency

  • Low Potent API
  • High Potent API

By Type of FDF

  • Originator FDF
  • Generic FDF

By Dosage Form

  • Oral Solids
  • Liquids
  • Emulsions
  • Other Dosage Forms

By Type of Oral Solid

  • Tablets
  • Capsules
  • Others

By Type of Packaging Offered

  • Bottles
  • Blister Packs
  • Vials
  • Prefilled Syringes
  • Cartridges
  • Ampoules
  • Oral Liquid Bottles
  • Others

By Scale of Operation

  • Clinical
  • Commercial

By End User

  • Small
  • Mid-sized
  • Large and Very Large

By Geographical Regions

  • North America
  • US
  • Canada
  • Europe
  • Belgium
  • Switzerland
  • UK
  • Germany
  • Ireland
  • Netherlands
  • Italy
  • France
  • Sweden
  • Rest of Europe

Asia-Pacific and Rest of the World

  • China
  • India
  • Japan
  • Korea
  • Rest of Asia-Pacific and Other Countries

Pharmaceutical Contract Manufacturing Market: Key Segments

The Manufacturing of Low Potent APIs Predominates the Pharmaceutical Contract Manufacturing Market

At present, low potent APIs account for 85% of the total market share. This is mainly due to their large-scale manufacturing and scalable methods. In addition, these APIs are utilized by pharmaceutical companies for treating different illnesses, including diabetes and infectious diseases. This extensive usage results in persistently elevated demand worldwide. Notably, the segment of highly potent APIs is expected to expand at a quicker rate. The increasing need for targeted treatments and precision medications fuels this expansion, as these therapies prove to be very effective even at minimal doses because of their strong therapeutic benefits.

Oral Solid Dosage Forms Dominate in the Pharmaceutical Contract Manufacturing Sector with Unmatched Demand

The oral solid dosage manufacturing sector represents approximately 55% of the total revenue in the pharma contract manufacturing market. This results from their low cost, convenience for patients, and effectiveness in mass production. In the future, the liquids category is expected to demonstrate greater growth in the pharmaceutical contract manufacturing market throughout the forecast .

North America Dominates the Pharmaceutical Contract Manufacturing Domain

North America leads the pharmaceutical contract manufacturing market, capturing approximately 45% of total revenue. The presence of a highly developed pharmaceutical sector, robust regulatory systems, and established leading global drug firms is driving the demand for pharmaceutical contract manufacturers in this region.

Primary Research Overview

The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The market report includes detailed transcripts of interviews conducted with the following individuals:

  • President and Chief Executive Officer, Corporate Strategy and Business Development, Mid-sized Company, US
  • Former Chief Executive Officer, Large Company, Switzerland
  • Former Vice President Business Development, Marketing, and IP, Mid-sized Company, Israel
  • Director, Operations, Mid-sized Company, India
  • Former Director of Business Development, Large Company, US
  • Former Director, Commercial Development, Cell Therapy, Mid-sized Company, Switzerland
  • Former Director, Pharmaceuticals Marketing, Large Company, France
  • Digitalization and Artificial Intelligence Manager, Large Company, Switzerland

Example Players in Pharmaceutical Contract Manufacturing Market

  • Albemarle
  • Aspen Pharmacare
  • Bausch Health Sciences
  • Catalent
  • Delpharm
  • Eurofins Scientific
  • Evonik Industries
  • Fareva
  • Fresenius Kabi
  • Intas Pharmaceuticals
  • Lonza
  • Micro Labs
  • Nipro Patch
  • Patheon
  • PiSA Farmaceutica
  • Recipharm
  • Sandoz
  • West Pharmaceutical Services
  • Wockhardt
  • WuXi AppTec

Pharmaceutical Contract Manufacturing Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the pharmaceutical contract manufacturing market, focusing on key market segments, including [A] type of product manufactured, [B] type of API, [C] API potency, [D] type of FDF, [E] dosage form, [F] type of oral solid [G] type of packaging offered [H] scale of operation, [I] end user and [J] geographical regions.
  • Market Landscape: A detailed overview of the current market landscape of companies engaged in offering contract manufacturing services for small molecules, along with information on several relevant parameters, such as [A] year of establishment, [B] location of manufacturing facility, [C] type of offering, [D] type of pharmaceutical product manufactured, [E] scale of operation, [F] type of service offered, [G] type of finished dosage form manufactured, [H] type of packaging offered.
  • Company Profiles: In-depth profiles of prominent players North America, Europe and Asia-Pacific that are engaged in the peptide therapeutics manufacturing market based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
  • Make versus Buy Framework: A qualitative analysis highlighting various factors that need to be taken into consideration by pharmaceutical drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • Mergers and Acquisitions: A detailed analysis of the various mergers and acquisitions in this domain, based on several relevant parameters, such as [A] year of agreement, [B] type of agreement, [C] geography, [D] most active players (in terms of number of agreements), ownership change matrix and key value drivers of the acquisition agreement.
  • Recent Expansions: A detailed analysis of expansions that have taken place in the pharmaceutical contract manufacturing domain, along with analysis on several relevant parameters, such as [A] year of expansion, [B] status of expansion, [C] type of expansion, [D] location of facility, [E] amount invested, [F] type of pharmaceutical product manufactured, [G] type of service offered and [H] most active players.
  • Regional Capability Analysis: A detailed regional capability of pharmaceutical contract manufacturing facilities in different regions (North America, Europe, Asia-Pacific and Rest of the World) across the globe.
  • Capacity Analysis: An estimate an estimate of the overall installed capacity for the manufacturing of pharmaceuticals, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity, based on [A] size of manufacturer (small, mid-sized, and large and very large) and [B] geography (North America, Europe, Asia-Pacific and Rest of the World).
  • Demand Analysis: An informed estimate of the annual demand for small molecule drugs, across several relevant parameters, such as [A] scale of operation, [B] type of API, [C] potency of API and [D] geographical regions.
  • Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the global pharmaceutical contract manufacturing market. It also features identification and analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

Key Questions Answered in this Report

  • Which are the leading companies in pharmaceutical contract manufacturing market?
  • Which region dominates the pharmaceutical contract manufacturing market?
  • What are the key trends observed in the pharmaceutical contract manufacturing market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by pharmaceutical contract manufacturers?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
  • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

  • Complementary PPT Insights Pack
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Report Coverage
  • 1.3. Market Segmentation
  • 1.4. Key Market Insights
  • 1.5. Market Share Insights
  • 1.6. Key Questions Asked

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

  • 5.1. Executive Summary: Market Landscape
  • 5.2. Executive Summary: Market Trends
  • 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Type of Third-party Manufacturers
  • 6.3. Overview of Pharmaceutical Contract Manufacturing
  • 6.4. Evolution of Pharmaceutical Contract Manufacturing
    • 6.4.1. Traditional Pharmaceutical Contract Manufacturing Organizations
    • 6.4.2. Modern Pharmaceutical Contract Manufacturing Organizations
  • 6.5. Need for Outsourcing in the Pharmaceutical Industry
  • 6.6. Recent Developments in the Pharmaceutical Contract Manufacturing Industry
    • 6.6.1. Integration of Artificial Intelligence
    • 6.6.2. Strategic Partnerships and Collaborations
      • 6.6.2.1. Strategic Long-Term Alliance
      • 6.6.2.2. Flexible Short-Term Partnership Agreements
    • 6.6.3. Integrated End-to-End Business Model
    • 6.6.4. Dependence on Software Service Providers
  • 6.7. Services Offered by Contract Manufacturing Organizations
  • 6.8. Key Considerations while Selecting a Contract Manufacturing Organization
  • 6.9. Risks and Challenges Associated with Outsourcing Pharmaceutical Manufacturing Operations
  • 6.10. Future Perspectives

7. PHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS: REGULATORY LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Regulatory Landscape in North America
    • 7.2.1. Landscape in the US
    • 7.2.2. Landscape in Canada
  • 7.3. Regulatory Landscape in Europe
  • 7.4. Regulatory Landscape in Asia-Pacific and Rest of the World
    • 7.4.1. Landscape in China
    • 7.4.2. Landscape in India
    • 7.4.3. Landscape in Japan
    • 7.4.4. Landscape in South Korea
    • 7.4.5. Landscape in Australia
    • 7.4.6. Landscape in Brazil
  • 7.5. Analysis of Pharmaceutical Contract Manufacturing Organizations by Approval Received from Regulatory Authorities
  • 7.6. Regulatory Landscape: Regional Benchmarking Analysis

8. PHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS: MARKET LANDSCAPE

  • 8.1. Chapter Overview
  • 8.2. Pharmaceutical Contract Manufacturing Organizations: Overall Market Landscape
    • 8.2.1. Analysis by Year of Establishment
    • 8.2.2. Analysis by Company Size
    • 8.2.3. Analysis by Location of Headquarters (Region)
    • 8.2.4. Analysis by Location of Headquarters (Country)
    • 8.2.5. Analysis by Location of Manufacturing Facility (Region)
    • 8.2.6. Analysis by Type of Offering
    • 8.2.7. Analysis by Type of Pharmaceutical Product Manufactured
    • 8.2.8. Analysis by Scale of Operation
    • 8.2.9. Analysis by Type of Service Offered
    • 8.2.10. Analysis by Finished Dosage Form Manufactured
    • 8.2.11. Analysis by Type of Packaging Offered

9. COMPANY PROFILES: LEADING PLAYERS

  • 9.1. Chapter Overview
  • 9.2. Pharmaceutical Contract Manufacturing Organizations based in North America
    • 9.2.1. Albemarle
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Information
      • 9.2.1.3. Service Portfolio
      • 9.2.1.4. Recent Developments and Future Outlook
  • similar details are presented for other below mentioned players based on information in the public domain
    • 9.2.2. Bausch Health Services
    • 9.2.3. Catalent
    • 9.2.4. Patheon
    • 9.2.5. PiSA Farmaceutica
    • 9.2.6. West Pharmaceutical Services
  • 9.3. Pharmaceutical Contract Manufacturing Organizations based in Europe
    • 9.3.1. Delpharm
    • 9.3.2. Eurofins Scientific
    • 9.3.3. Evonik Industries
    • 9.3.4. Fareva
    • 9.3.5. Fresenius Kabi
    • 9.3.6. Lonza
    • 9.3.7. Recipharm
    • 9.3.8. Sandoz
  • 9.4. Pharmaceutical Contract Manufacturing Organizations based in Asia-Pacific and Rest of the World
    • 9.4.1. Aspen Pharmacare
    • 9.4.2. Intas Pharmaceuticals
    • 9.4.3. Micro Labs
    • 9.4.4. Nipro Patch
    • 9.4.5. WuXi AppTec
    • 9.4.6. Wockhardt

10. MAKE VERSUS BUY DECISION FRAMEWORK

  • 10.1. Chapter Overview
  • 10.2. Assumptions and Key Parameters
  • 10.3. Pharmaceutical Contract Manufacturers: Make versus Buy Decision Making
    • 10.3.1. Scenario 1
    • 10.3.2. Scenario 2
    • 10.3.3. Scenario 3
    • 10.3.4. Scenario 4
  • 10.4. Concluding Remarks

11. MERGERS AND ACQUISITIONS

  • 11.1. Chapter Overview
  • 11.2. Types of Mergers and Acquisitions
  • 11.3. Pharmaceutical Contract Manufacturing Organizations: Mergers and Acquisitions
    • 11.3.1. Analysis by Year of Agreement
    • 11.3.2. Analysis by Type of Agreement
    • 11.3.3. Analysis by Geography
      • 11.3.3.1. Local and International Agreements
      • 11.3.3.2. Intracontinental and Intercontinental Agreements
    • 11.3.4. Most Active Players: Analysis by Number of Agreements
    • 11.3.5. Ownership Change Matrix
    • 11.3.6. Analysis by Key Value Drivers

12. RECENT EXPANSIONS

  • 12.1. Chapter Overview
  • 12.2. Type of Expansions
  • 12.3. Pharmaceutical Contract Manufacturing Organizations: Recent Expansions
    • 12.3.1. Analysis by Year of Expansion
    • 12.3.2. Analysis by Status of Expansion
    • 12.3.3. Analysis by Type of Expansion
    • 12.3.4. Analysis by Year and Type of Expansion
    • 12.3.5. Analysis by Location of Facility (Region)
    • 12.3.6. Analysis by Location of Facility (Country)
    • 12.3.7. Analysis by Type of Expansion and Location of Facility (Region)
    • 12.3.8. Analysis of Amount Invested by Year of Expansion
    • 12.3.9. Analysis of Amount Invested by Type of Expansion
    • 12.3.10. Analysis by Type of Pharmaceutical Product Manufactured
    • 12.3.11. Analysis by Type of Service Offered
    • 12.3.12. Most Active Players: Analysis by Number of Expansions
    • 12.3.13. Most Active Players: Analysis by Amount Invested

13. REGIONAL CAPABILITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Assumptions and Key Parameters
  • 13.3. Overall Landscape of Pharmaceutical Contract Manufacturing Facilities
    • 13.3.1. Pharmaceutical Contract Manufacturing Facilities in North America
    • 13.3.2. Pharmaceutical Contract Manufacturing Facilities in Europe
    • 13.3.3. Pharmaceutical Contract Manufacturing Facilities in Asia-Pacific
    • 13.3.4. Pharmaceutical Contract Manufacturing Facilities in Rest of the World

14. CAPACITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Pharmaceutical Contract Manufacturing: Global Production Capacity
    • 14.3.1. Analysis by Company Size
    • 14.3.2. Analysis by Scale of Operation
    • 14.3.3. Analysis by Location of Manufacturing Facility
      • 14.3.3.1. Pharmaceutical Contract Manufacturing Capacity in North America
      • 14.3.3.2. Pharmaceutical Contract Manufacturing Capacity in Europe
      • 14.3.3.3. Pharmaceutical Contract Manufacturing Capacity in Asia-Pacific
  • 14.4. Concluding Remarks

15. DEMAND ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Global Demand for Pharmaceutical Contract Manufacturing
    • 15.3.1. Demand for Pharmaceutical Contract Manufacturing: Analysis by Scale of Operation
    • 15.3.2. Demand for Pharmaceutical Contract Manufacturing: Analysis by Type of API
    • 15.3.3. Demand for Pharmaceutical Contract Manufacturing: Analysis by Potency of API
    • 15.3.4. Demand for Pharmaceutical Contract Manufacturing: Analysis by Geographical Regions

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 16.1. Chapter Overview
  • 16.2. Market Drivers
  • 16.3. Market Restraints
  • 16.4. Market Opportunities
  • 16.5. Market Challenges
  • 16.6. Conclusion

17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Methodology
  • 17.3. Global Pharmaceutical Contract Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 17.3.1. Roots Analysis Perspective on Market Growth
    • 17.3.2. Scenario Analysis
      • 17.3.2.1. Conservative Scenario
      • 17.3.2.2. Optimistic Scenario
  • 17.4. Key Market Segments

18. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF PRODUCT MANUFACTURED

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Pharmaceutical Contract Manufacturing Market: Distribution by Type of Product Manufactured
    • 18.3.1. Pharmaceutical Contract Manufacturing Market for API and Intermediates: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 18.3.2. Pharmaceutical Contract Manufacturing Market for FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.4. Data Triangulation and Validation

19. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF API

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Pharmaceutical Contract Manufacturing Market: Distribution by Type of API
    • 19.3.1. Pharmaceutical Contract Manufacturing Market for Originator APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 19.3.2. Pharmaceutical Contract Manufacturing Market for Generic APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 19.4. Data Triangulation and Validation

20. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY API POTENCY

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Pharmaceutical Contract Manufacturing Market: Distribution by API Potency
    • 20.3.1. Pharmaceutical Contract Manufacturing Market for Low Potent APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 20.3.2. Pharmaceutical Contract Manufacturing Market for High Potent APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.4. Data Triangulation and Validation

21. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF FDF

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Pharmaceutical Contract Manufacturing Market: Distribution by Type of FDF
    • 21.3.1. Pharmaceutical Contract Manufacturing Market for Originator FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 21.3.2. Pharmaceutical Contract Manufacturing Market for Generic FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 21.4. Data Triangulation and Validation

22. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY DOSAGE FORM

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Pharmaceutical Contract Manufacturing Market: Distribution by Dosage Form
    • 22.3.1. Pharmaceutical Contract Manufacturing Market for Oral Solids: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.3.2. Pharmaceutical Contract Manufacturing Market for Liquids: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.3.3. Pharmaceutical Contract Manufacturing Market for Emulsions: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.3.4. Pharmaceutical Contract Manufacturing Market for Other Dosage Forms: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 22.4. Data Triangulation and Validation

23. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY ORAL SOLIDS

  • 23.1. Chapter Overview
  • 23.2. Key Assumptions and Methodology
  • 23.3. Pharmaceutical Contract Manufacturing Market: Distribution by Oral Solids
    • 23.3.1. Pharmaceutical Contract Manufacturing Market for Tablets: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2. Pharmaceutical Contract Manufacturing Market for Capsules: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.3. Pharmaceutical Contract Manufacturing Market for Other Solid Doses: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.4. Data Triangulation and Validation

24. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF PACKAGING OFFERED

  • 24.1. Chapter Overview
  • 24.2. Key Assumptions and Methodology
  • 24.3. Pharmaceutical Contract Manufacturing Market: Distribution by Type of Packaging Offered
    • 24.3.1. Pharmaceutical Contract Manufacturing Market for Bottles: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.2. Pharmaceutical Contract Manufacturing Market for Blister Packs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.3. Pharmaceutical Contract Manufacturing Market for Oral Liquid Bottles: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.4. Pharmaceutical Contract Manufacturing Market for Vials: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.5. Pharmaceutical Contract Manufacturing Market for Prefilled Syringe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.6. Pharmaceutical Contract Manufacturing Market for Cartridges: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.7. Pharmaceutical Contract Manufacturing Market for Ampoules: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.8. Pharmaceutical Contract Manufacturing Market for Other Types of Packaging: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.4. Data Triangulation and Validation

25. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. Pharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
    • 25.3.1. Pharmaceutical Contract Manufacturing Market for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.3.2. Pharmaceutical Contract Manufacturing Market for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.4. Data Triangulation and Validation

26. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END-USER

  • 26.1. Chapter Overview
  • 26.2. Key Assumptions and Methodology
  • 26.3. Pharmaceutical Contract Manufacturing Market: Distribution by End-user
    • 26.3.1. Pharmaceutical Contract Manufacturing Market for Small Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.3.2. Pharmaceutical Contract Manufacturing Market for Mid-sized Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.3.3. Pharmaceutical Contract Manufacturing Market for Large and Very Large Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.4. Data Triangulation and Validation

27. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS

  • 27.1. Chapter Overview
  • 27.2. Key Assumptions and Methodology
  • 27.3. Pharmaceutical Contract Manufacturing Market: Distribution by Geographical Regions
    • 27.3.1. Pharmaceutical Contract Manufacturing Market in North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.1.1. Pharmaceutical Contract Manufacturing Market in the US: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.1.2. Pharmaceutical Contract Manufacturing Market in Canada: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 27.3.2. Pharmaceutical Contract Manufacturing Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.2.1. Pharmaceutical Contract Manufacturing Market in Germany: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.2.2. Pharmaceutical Contract Manufacturing Market in France: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.2.3. Pharmaceutical Contract Manufacturing Market in the UK: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.2.4. Pharmaceutical Contract Manufacturing Market in Italy: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.2.5. Pharmaceutical Contract Manufacturing Market in Spain: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.2.6. Pharmaceutical Contract Manufacturing Market in rest of the Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 27.3.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.3.1. Pharmaceutical Contract Manufacturing Market in China: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.3.2. Pharmaceutical Contract Manufacturing Market in Japan: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.3.3. Pharmaceutical Contract Manufacturing Market in India: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.3.4. Pharmaceutical Contract Manufacturing Market in South Korea: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.3.5. Pharmaceutical Contract Manufacturing Market in Australia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.3.6. Pharmaceutical Contract Manufacturing Market in rest of the Asia-Pacific: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 27.3.4. Pharmaceutical Contract Manufacturing Market in Latin America
      • 27.3.4.1. Pharmaceutical Contract Manufacturing Market in Brazil: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.4.2. Pharmaceutical Contract Manufacturing Market in Argentina: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.4.3. Pharmaceutical Contract Manufacturing Market in rest of the Latin America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 27.3.5. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa
      • 27.3.5.1. Pharmaceutical Contract Manufacturing Market in Saudi Arabia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.5.2. Pharmaceutical Contract Manufacturing Market in Egypt: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 27.3.5.3. Pharmaceutical Contract Manufacturing Market in rest of the Middle East and North Africa: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.4. Market Dynamics Assessment
    • 27.4.1. Market Movement Analysis
    • 27.4.2. Penetration Growth (P-G) Matrix
  • 27.5. Data Triangulation and Validation

28. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: NORTH AMERICA

  • 28.1. Pharmaceutical Contract Manufacturing Market in North America: Distribution by Type of Product Manufactured
    • 28.1.1. Pharmaceutical Contract Manufacturing Market in North America for API and Intermediates: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.1.2. Pharmaceutical Contract Manufacturing Market in North America for FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 28.2. Pharmaceutical Contract Manufacturing Market in North America: Distribution by Type of API
    • 28.2.1. Pharmaceutical Contract Manufacturing Market in North America for Generic APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.2.2. Pharmaceutical Contract Manufacturing Market in North America for Innovator APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 28.3. Pharmaceutical Contract Manufacturing Market in North America: Distribution by Potency of API
    • 28.3.1. Pharmaceutical Contract Manufacturing Market in North America for Low Potent APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.3.2. Pharmaceutical Contract Manufacturing Market in North America for High Potent APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 28.4. Pharmaceutical Contract Manufacturing Market in North America: Distribution by Type of FDF
    • 28.4.1. Pharmaceutical Contract Manufacturing Market in North America for Generic FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.4.2. Pharmaceutical Contract Manufacturing Market in North America for Innovator FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 28.5. Pharmaceutical Contract Manufacturing Market in North America: Distribution by Dosage Form
    • 28.5.1. Pharmaceutical Contract Manufacturing Market in North America for Oral Solids: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.5.2. Pharmaceutical Contract Manufacturing Market in North America for Liquids: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.5.3. Pharmaceutical Contract Manufacturing Market in North America for Emulsions: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.5.4. Pharmaceutical Contract Manufacturing Market in North America for Other Dosage Forms: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 28.6. Pharmaceutical Contract Manufacturing Market in North America: Distribution by Oral Solids
    • 28.6.1. Pharmaceutical Contract Manufacturing Market in North America for Tablets: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.6.2. Pharmaceutical Contract Manufacturing Market in North America for Capsules: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.6.3. Pharmaceutical Contract Manufacturing Market in North America for Emulsions: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 28.7. Pharmaceutical Contract Manufacturing Market in North America: Distribution by Type of Packaging Offered
    • 28.7.1. Pharmaceutical Contract Manufacturing Market in North America for Bottles: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.7.2. Pharmaceutical Contract Manufacturing Market in North America for Blisters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.7.3. Pharmaceutical Contract Manufacturing Market in North America for Parenterals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.7.4. Pharmaceutical Contract Manufacturing Market in North America for Oral Liquid Bottles: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.7.5. Pharmaceutical Contract Manufacturing Market in North America for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 28.8. Pharmaceutical Contract Manufacturing Market in North America: Distribution by End-user
    • 28.8.1. Pharmaceutical Contract Manufacturing Market in North America for Small Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.8.2. Pharmaceutical Contract Manufacturing Market in North America for Mid-sized Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.8.3. Pharmaceutical Contract Manufacturing Market in North America for Large and Very Large Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 28.9. Pharmaceutical Contract Manufacturing Market in North America: Distribution by Scale of Operation
    • 28.9.1. Pharmaceutical Contract Manufacturing Market in North America for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.9.2. Pharmaceutical Contract Manufacturing Market in North America for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EUROPE

  • 29.1. Pharmaceutical Contract Manufacturing Market in Europe: Distribution by Type of Product Manufactured
    • 29.1.1. Pharmaceutical Contract Manufacturing Market in Europe for API and Intermediates: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.1.2. Pharmaceutical Contract Manufacturing Market in Europe for FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.2. Pharmaceutical Contract Manufacturing Market in Europe: Distribution by Type of API
    • 29.2.1. Pharmaceutical Contract Manufacturing Market in Europe for Generic APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.2.2. Pharmaceutical Contract Manufacturing Market in Europe for Innovator APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.3. Pharmaceutical Contract Manufacturing Market in Europe: Distribution by Potency of API
    • 29.3.1. Pharmaceutical Contract Manufacturing Market in Europe for Low Potent APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.3.2. Pharmaceutical Contract Manufacturing Market in Europe for High Potent APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.4. Pharmaceutical Contract Manufacturing Market in Europe: Distribution by Type of FDF
    • 29.4.1. Pharmaceutical Contract Manufacturing Market in Europe for Generic FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.4.2. Pharmaceutical Contract Manufacturing Market in Europe for Innovator FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.5. Pharmaceutical Contract Manufacturing Market in Europe: Distribution by Dosage Form
    • 29.5.1. Pharmaceutical Contract Manufacturing Market in Europe for Oral Solids: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.5.2. Pharmaceutical Contract Manufacturing Market in Europe for Liquids: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.5.3. Pharmaceutical Contract Manufacturing Market in Europe for Emulsions: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.5.4. Pharmaceutical Contract Manufacturing Market in Europe for Other Dosage Forms: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.6. Pharmaceutical Contract Manufacturing Market in Europe: Distribution by Oral Solids
    • 29.6.1. Pharmaceutical Contract Manufacturing Market in Europe for Tablets: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.6.2. Pharmaceutical Contract Manufacturing Market in Europe for Capsules: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.6.3. Pharmaceutical Contract Manufacturing Market in Europe for Emulsions: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.7. Pharmaceutical Contract Manufacturing Market in Europe: Distribution by Type of Packaging Offered
    • 29.7.1. Pharmaceutical Contract Manufacturing Market in Europe for Bottles: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.7.2. Pharmaceutical Contract Manufacturing Market in Europe for Blisters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.7.3. Pharmaceutical Contract Manufacturing Market in Europe for Parenterals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.7.4. Pharmaceutical Contract Manufacturing Market in Europe for Oral Liquid Bottles: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.7.5. Pharmaceutical Contract Manufacturing Market in Europe for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.8. Pharmaceutical Contract Manufacturing Market in Europe: Distribution by End-user
    • 29.8.1. Pharmaceutical Contract Manufacturing Market in Europe for Small Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.8.2. Pharmaceutical Contract Manufacturing Market in Europe for Mid-sized Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.8.3. Pharmaceutical Contract Manufacturing Market in Europe for Large and Very Large Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.9. Pharmaceutical Contract Manufacturing Market in Europe: Distribution by Scale of Operation
    • 29.9.1. Pharmaceutical Contract Manufacturing Market in Europe for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.9.2. Pharmaceutical Contract Manufacturing Market in Europe for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

30. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ASIA-PACIIFC

  • 30.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Type of Product Manufactured
    • 30.1.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for API and Intermediates: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.1.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Type of API
    • 30.2.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Generic APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.2.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Innovator APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Potency of API
    • 30.3.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Low Potent APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for High Potent APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.4. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Type of FDF
    • 30.4.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Generic FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.4.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Innovator FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.5. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Dosage Form
    • 30.5.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Oral Solids: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.5.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Liquids: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.5.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Emulsions: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.5.4. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Other Dosage Forms: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.6. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Oral Solids
    • 30.6.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Tablets: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.6.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Capsules: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.6.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Emulsions: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.7. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Type of Packaging Offered
    • 30.7.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Bottles: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.7.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Blisters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.7.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Parenterals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.7.4. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Oral Liquid Bottles: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.7.5. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.8. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by End-user
    • 30.8.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Small Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.8.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Mid-sized Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.8.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Large and Very Large Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.9. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
    • 30.9.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.9.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

31. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REST OF THE WORLD

  • 31.1. Pharmaceutical Contract Manufacturing Market in Rest of the World: Distribution by Type of Product Manufactured
    • 31.1.1. Pharmaceutical Contract Manufacturing Market in Rest of the World for API and Intermediates: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.1.2. Pharmaceutical Contract Manufacturing Market in Rest of the World for FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 31.2. Pharmaceutical Contract Manufacturing Market in Rest of the World: Distribution by Type of API
    • 31.2.1. Pharmaceutical Contract Manufacturing Market in Rest of the World for Generic APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.2.2. Pharmaceutical Contract Manufacturing Market in Rest of the World for Innovator APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 31.3. Pharmaceutical Contract Manufacturing Market in Rest of the World: Distribution by Potency of API
    • 31.3.1. Pharmaceutical Contract Manufacturing Market in Rest of the World for Low Potent APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.3.2. Pharmaceutical Contract Manufacturing Market in Rest of the World for High Potent APIs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 31.4. Pharmaceutical Contract Manufacturing Market in Rest of the World: Distribution by Type of FDF
    • 31.4.1. Pharmaceutical Contract Manufacturing Market in Rest of the World for Generic FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.4.2. Pharmaceutical Contract Manufacturing Market in Rest of the World for Innovator FDFs: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 31.5. Pharmaceutical Contract Manufacturing Market in Rest of the World: Distribution by Dosage Form
    • 31.5.1. Pharmaceutical Contract Manufacturing Market in Rest of the World for Oral Solids: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.5.2. Pharmaceutical Contract Manufacturing Market in Rest of the World for Liquids: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.5.3. Pharmaceutical Contract Manufacturing Market in Rest of the World for Emulsions: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.5.4. Pharmaceutical Contract Manufacturing Market in Rest of the World for Other Dosage Forms: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 31.6. Pharmaceutical Contract Manufacturing Market in Rest of the World: Distribution by Oral Solids
    • 31.6.1. Pharmaceutical Contract Manufacturing Market in Rest of the World for Tablets: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.6.2. Pharmaceutical Contract Manufacturing Market in Rest of the World for Capsules: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.6.3. Pharmaceutical Contract Manufacturing Market in Rest of the World for Emulsions: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 31.7. Pharmaceutical Contract Manufacturing Market in Rest of the World: Distribution by Type of Packaging Offered
    • 31.7.1. Pharmaceutical Contract Manufacturing Market in Rest of the World for Bottles: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.7.2. Pharmaceutical Contract Manufacturing Market in Rest of the World for Blisters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.7.3. Pharmaceutical Contract Manufacturing Market in Rest of the World for Parenterals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.7.4. Pharmaceutical Contract Manufacturing Market in Rest of the World for Oral Liquid Bottles: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.7.5. Pharmaceutical Contract Manufacturing Market in Rest of the World for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 31.8. Pharmaceutical Contract Manufacturing Market in Rest of the World: Distribution by End-user
    • 31.8.1. Pharmaceutical Contract Manufacturing Market in Rest of the World for Small Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.8.2. Pharmaceutical Contract Manufacturing Market in Rest of the World for Mid-sized Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.8.3. Pharmaceutical Contract Manufacturing Market in Rest of the World for Large and Very Large Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 31.9. Pharmaceutical Contract Manufacturing Market in Rest of the World: Distribution by Scale of Operation
    • 31.9.1. Pharmaceutical Contract Manufacturing Market in Rest of the World for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 31.9.2. Pharmaceutical Contract Manufacturing Market in Rest of the World for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • *Detailed information on Chapters 28-31 is available in the Excel Data Packs shared along with the report**

32. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY LEADING PLAYERS

  • 32.1. Chapter Overview
  • 32.2. Key Assumptions and Methodology
  • 32.3. Pharmaceutical Contract Manufacturing Market by Leading Players
  • 32.4. Data Triangulation and Validation

33. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES

  • 33.1. Chapter Overview
  • 33.2. Overview of Small Molecule and Large Molecule Drugs / Therapies
    • 33.2.1. Comparison of General Characteristics
    • 33.2.2. Comparison of Key Specifications
    • 33.2.3. Comparison of Manufacturing Processes
    • 33.2.4. Comparison of Key Manufacturing-related Challenges

34. CONCLUDING INSIGHTS

35. EXECUTIVE INSIGHTS

36. APPENDIX I: TABULATED DATA

37. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
  • Table 7.2 Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
  • Table 7.3 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
  • Table 8.1 List of Pharmaceutical Contract Manufacturing Organizations: Information on Year of Establishment, Company Size, Location of Headquarters
  • Table 8.2 Pharmaceutical Contract Manufacturing Organizations: Information on Type of Offering, Type of Pharmaceutical Product Manufactured and Scale of Operation
  • Table 8.3 Pharmaceutical Contract Manufacturing Organizations: Information on Type of Service Offered
  • Table 8.4 Pharmaceutical Contract Manufacturing Organizations: Information on Type of Finished Dosage Form Manufactured
  • Table 8.5 Pharmaceutical Contract Manufacturing Organizations: Information on Type of Packaging Offered
  • Table 9.1 Pharmaceutical Contract Manufacturing: List of Companies Profiled
  • Table 9.2 Albemarle: Company Overview
  • Table 9.3 Albemarle: Service Portfolio
  • Table 9.4 Bausch Health Sciences: Company Overview
  • Table 9.5 Bausch Health Sciences: Service Portfolio
  • Table 9.6 Bausch Health Sciences: Recent Developments and Future Outlook
  • Table 9.7 Catalent: Company Overview
  • Table 9.8 Catalent: Service Portfolio
  • Table 9.9 Catalent: Recent Developments and Future Outlook
  • Table 9.10 Patheon: Company Overview
  • Table 9.11 Patheon: Service Portfolio
  • Table 9.12 Thermo Fischer Scientific (Parent Company of Patheon): Recent Developments and Future Outlook
  • Table 9.13 PiSA Farmaceutica: Company Overview
  • Table 9.14 PiSA Farmaceutica: Service Portfolio
  • Table 9.15 West Pharmaceutical Services: Company Overview
  • Table 9.16 West Pharmaceutical Services: Service Portfolio
  • Table 9.17 West Pharmaceutical Services: Recent Developments and Future Outlook
  • Table 9.18 Delpharm: Company Overview
  • Table 9.19 Delpharm: Service Portfolio
  • Table 9.20 Eurofins Scientific: Company Overview
  • Table 9.21 Eurofins Scientific: Service Portfolio
  • Table 9.22 Eurofins Scientific: Recent Developments and Future Outlook
  • Table 9.23 Evonik Industries: Company Overview
  • Table 9.24 Evonik Industries: Service Portfolio
  • Table 9.25 Evonik Industries: Recent Developments and Future Outlook
  • Table 9.26 Fareva: Company Overview
  • Table 9.27 Fareva: Service Portfolio
  • Table 9.28 Fareva: Recent Developments and Future Outlook
  • Table 9.29 Fresenius Kabi: Company Overview
  • Table 9.30 Fresenius Kabi: Service Portfolio
  • Table 9.31 Fresenius Kabi: Recent Developments and Future Outlook
  • Table 9.32 Lonza: Company Overview
  • Table 9.33 Lonza: Service Portfolio
  • Table 9.34 Lonza: Recent Developments and Future Outlook
  • Table 9.35 Recipharm: Company Overview
  • Table 9.36 Recipharm: Service Portfolio
  • Table 9.37 Recipharm: Recent Developments and Future Outlook
  • Table 9.38 Sandoz: Company Overview
  • Table 9.39 Sandoz: Service Portfolio
  • Table 9.40 Sandoz: Recent Developments and Future Outlook
  • Table 9.41 Aspen Pharmacare: Company Overview
  • Table 9.42 Aspen Pharmacare: Service Portfolio
  • Table 9.43 Intas Pharmaceuticals: Company Overview
  • Table 9.44 Intas Pharmaceuticals: Service Portfolio
  • Table 9.45 Micro Labs: Company Overview
  • Table 9.46 Micro Labs: Service Portfolio
  • Table 9.47 Nipro Patch: Company Overview
  • Table 9.48 Nipro Patch: Service Portfolio
  • Table 9.49 WuXi AppTec: Company Overview
  • Table 9.50 WuXi AppTec: Service Portfolio
  • Table 9.51 WuXi AppTec: Recent Developments and Future Outlook
  • Table 9.52 Wockhardt: Company Overview
  • Table 9.53 Wockhardt: Service Portfolio
  • Table 11.1 Pharmaceutical Contract Manufacturing Organizations: List of Mergers and Acquisitions, Since Q3 2024
  • Table 11.2 Mergers and Acquisitions: Information on Key Value Drivers
  • Table 12.1 Pharmaceutical Contract Manufacturing: List of Expansions, Since Q3 2024
  • Table 12.2 Pharmaceutical Contract Manufacturing Organizations: Type of Pharmaceutical Product Manufactured and Type of Service Offered
  • Table 13.1 Pharmaceutical Contract Manufacturing Organizations: Information on Manufacturing Facilities in North America
  • Table 13.2 Pharmaceutical Contract Manufacturing Organizations: Information on Manufacturing Facilities in Europe
  • Table 13.3 Pharmaceutical Contract Manufacturing Organizations: Information on Manufacturing Facilities in Asia-Pacific
  • Table 13.4 Pharmaceutical Contract Manufacturing Organizations: Information on Manufacturing Facilities in Rest of the World
  • Table 14.1 Pharmaceutical Contract Manufacturers: Information on Production Capacity (Sample Dataset)
  • Table 14.2 Pharmaceutical Contract Manufacturing: Average Production Capacity Based on Company Size (Sample Dataset)
  • Table 14.3 Global Pharmaceutical Contract Manufacturing Capacity: Distribution by Company Size (in million units)
  • Table 28.1 List of Leading Pharmaceutical Contract Manufacturing Companies
  • Table 29.1 Small Molecules and Large Molecules: Strengths and Weaknesses
  • Table 29.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
  • Table 29.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
  • Table 31.1 Ajinomoto Althea: Key Highlights
  • Table 31.2 Bachem: Key Highlights
  • Table 31.3 CiVentiChem: Key Highlights
  • Table 31.4 CordenPharma: Key Highlights
  • Table 31.5 Helsinn: Key Highlights
  • Table 31.6 Novasep: Key Highlights
  • Table 31.7 Sovereign Pharma: Key Highlights
  • Table 31.8 Wavelength Pharmaceuticals: Key Highlights
  • Table 36.1 Pharmaceutical Contract Manufacturing Organizations: Distribution by Year of Establishment
  • Table 36.2 Pharmaceutical Contract Manufacturing Organizations: Distribution by Company Size
  • Table 36.3 Pharmaceutical Contract Manufacturing Organizations: Distribution by Location of Headquarters (Region)
  • Table 36.4 Pharmaceutical Contract Manufacturing Organizations: Distribution by Location of Headquarters (Country)
  • Table 36.5 Pharmaceutical Contract Manufacturing Organizations: Distribution by Location of Manufacturing Facility (Region)
  • Table 36.6 Pharmaceutical Contract Manufacturing Organizations: Distribution by Type of Offering
  • Table 36.7 Pharmaceutical Contract Manufacturing Organizations: Distribution by Type of Pharmaceutical Product Manufactured
  • Table 36.8 Pharmaceutical Contract Manufacturing Organizations: Distribution by Scale of Operation
  • Table 36.9 Pharmaceutical Contract Manufacturing Organizations: Distribution by Type of Service Offered
  • Table 36.10 Pharmaceutical Contract Manufacturing Organizations: Distribution by Type of Finished Dosage Form Manufactured
  • Table 36.11 Pharmaceutical Contract Manufacturing Organizations: Distribution by Type of Packaging Offered
  • Table 36.12 Albemarle: Business Segment-wise Financial Details (USD Billion), Since FY 2022
  • Table 36.13 Thermo Fischer Scientific (Parent Company of Patheon): Consolidated Financial Details (USD Billion), Since FY 2022
  • Table 36.14 West Pharmaceutical Services: Business Segment-wise Financial Details (USD Billion), Since FY 2022
  • Table 36.15 Eurofins Scientific: Consolidated Financial Details (EUR Billion), Since FY 2022
  • Table 36.16 Evonik Industries: Consolidated Financial Details (EUR Billion), Since FY 2022
  • Table 36.17 Fresenius Kabi: Consolidated Financial Details (EUR Billion), Since FY 2022
  • Table 36.18 Lonza: Business Segment-wise Financial Details (CHF Billion), Since FY 2022
  • Table 36.19 Aspen Pharmacare: Consolidated Financial Details (CER Billion), Since FY 2022
  • Table 36.20 WuXi AppTec: Consolidated Financial Details (RMB Billion), Since FY 2022
  • Table 36.21 Mergers and Acquisitions: Distribution by Year of Agreement
  • Table 36.22 Mergers and Acquisitions: Distribution by Type of Agreement
  • Table 36.23 Mergers and Acquisitions: Distribution by Local and International Agreements
  • Table 36.24 Mergers and Acquisitions: Distribution by Intracontinental and Intercontinental Agreements
  • Table 36.25 Most Active Players: Distribution by Number of Agreements
  • Table 36.26 Mergers and Acquisitions: Distribution by Ownership Change Matrix
  • Table 36.27 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Table 36.28 Recent Expansions: Distribution by Year of Expansion
  • Table 36.29 Recent Expansions: Distribution by Status of Expansion
  • Table 36.30 Recent Expansions: Distribution by Type of Expansion
  • Table 36.31 Recent Expansions: Distribution by Year and Type of Expansion
  • Table 36.32 Recent Expansions: Distribution by Location of Facility (Region)
  • Table 36.33 Recent Expansions: Distribution by Location of Facility (Country)
  • Table 36.34 Recent Expansions: Distribution by Distribution by Type of Expansion and Location of Facility (Region)
  • Table 36.35 Recent Expansions: Distribution of Amount Invested by Year of Expansion
  • Table 36.36 Recent Expansions: Distribution of Amount Invested by Type of Expansion
  • Table 36.37 Recent Expansions: Distribution by Type of Pharmaceutical Product Manufactured
  • Table 36.38 Recent Expansions: Distribution by Type of Service Offered
  • Table 36.39 Most Active Players: Distribution by Number of Expansions
  • Table 36.40 Most Active Players: Distribution by Amount Invested
  • Table 36.41 Global Capacity of Pharmaceutical Contract Manufacturers (in million units): Distribution by Range of Installed Capacity
  • Table 36.42 Global Capacity of Pharmaceutical Contract Manufacturers (in million units): Distribution by Company Size
  • Table 36.43 Global Capacity of Pharmaceutical Contract Manufacturers (in million units): Distribution by Scale of Operation
  • Table 36.44 Global Capacity of Pharmaceutical Contract Manufacturers (in million units): Distribution by Location of Manufacturing Facility
  • Table 36.45 Pharmaceutical Contract Manufacturing Capacity in North America
  • Table 36.46 Pharmaceutical Contract Manufacturing Capacity in Europe
  • Table 36.47 Pharmaceutical Contract Manufacturing Capacity in Asia-Pacific
  • Table 36.48 Pharmaceutical Contract Manufacturing Capacity in Rest of the World
  • Table 36.49 Global Demand for Pharmaceutical Contract Manufacturing, Historical Trends, Since 2020 and Forecasted Estimates, Till 2035 (in Metric Tons)
  • Table 36.50 Demand for Pharmaceutical Contract Manufacturing: Distribution by Scale of Operation, Historical Trends, Since 2020 and Forecasted Estimates, Till 2035 (in Metric Tons)
  • Table 36.51 Demand for Pharmaceutical Contract Manufacturing: Distribution by Type of API, Historical Trends, Since 2020 and Forecasted Estimates, Till 2035 (in Metric Tons)
  • Table 36.52 Demand for Pharmaceutical Contract Manufacturing: Distribution by Potency of API, Historical Trends, Since 2020 and Forecasted Estimates, Till 2035 (in Metric Tons)
  • Table 36.53 Demand for Pharmaceutical Contract Manufacturing: Distribution by Geographical Regions, Historical Trends, Since 2020 and Forecasted Estimates, Till 2035 (in Metric Tons)
  • Table 36.54 Global Pharmaceutical Contract Manufacturing Market, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.55 Global Pharmaceutical Contract Manufacturing Market, Forecasted Estimates, Till 2035: Conservative Scenario (USD Billion)
  • Table 36.56 Global Pharmaceutical Contract Manufacturing Market, Forecasted Estimates, Till 2035: Optimistic Scenario (USD Billion)
  • Table 36.57 Pharmaceutical Contract Manufacturing Market: Distribution by Type of Product Manufactured
  • Table 36.58 Pharmaceutical Contract Manufacturing Market for API and Intermediates, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.59 Pharmaceutical Contract Manufacturing Market for FDFs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.60 Pharmaceutical Contract Manufacturing Market: Distribution by Type of API
  • Table 36.61 Pharmaceutical Contract Manufacturing Market for Originator APIs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.62 Pharmaceutical Contract Manufacturing Market for Generic APIs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.63 Pharmaceutical Contract Manufacturing Market: Distribution by API Potency
  • Table 36.64 Pharmaceutical Contract Manufacturing Market for Low Potent APIs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.65 Pharmaceutical Contract Manufacturing Market for High Potent APIs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.66 Pharmaceutical Contract Manufacturing Market: Distribution by Type of FDF
  • Table 36.67 Pharmaceutical Contract Manufacturing Market for Originator FDFs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.68 Pharmaceutical Contract Manufacturing Market for Generic FDFs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.69 Pharmaceutical Contract Manufacturing Market: Distribution by Dosage Form
  • Table 36.70 Pharmaceutical Contract Manufacturing Market for Oral Solids, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.71 Pharmaceutical Contract Manufacturing Market for Liquids, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.72 Pharmaceutical Contract Manufacturing Market for Emulsions, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.73 Pharmaceutical Contract Manufacturing Market for Other Dosage Forms, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.74 Pharmaceutical Contract Manufacturing Market: Distribution by Type of Oral Solid
  • Table 36.75 Pharmaceutical Contract Manufacturing Market for Tablets, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.76 Pharmaceutical Contract Manufacturing Market for Capsules, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.77 Pharmaceutical Contract Manufacturing Market for Other Oral Solids, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.78 Pharmaceutical Contract Manufacturing Market: Distribution by Type of Packaging Offered
  • Table 36.79 Pharmaceutical Contract Manufacturing Market for Bottles, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.80 Pharmaceutical Contract Manufacturing Market for Blister Packs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.81 Pharmaceutical Contract Manufacturing Market for Oral Liquid Bottles, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.82 Pharmaceutical Contract Manufacturing Market for Vials, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.83 Pharmaceutical Contract Manufacturing Market for Prefilled Syringe, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.84 Pharmaceutical Contract Manufacturing Market for Cartridges, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.85 Pharmaceutical Contract Manufacturing Market for Ampoules, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.86 Pharmaceutical Contract Manufacturing Market for Other Types of Packaging, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.87 Pharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
  • Table 36.88 Pharmaceutical Contract Manufacturing Market for Clinical Scale, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.89 Pharmaceutical Contract Manufacturing Market for Commercial Scale, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.90 Pharmaceutical Contract Manufacturing Market: Distribution by End User
  • Table 36.91 Pharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.92 Pharmaceutical Contract Manufacturing Market for Mid-sized Companies, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.93 Pharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.94 Pharmaceutical Contract Manufacturing Market: Distribution by Geographical Region
  • Table 36.95 Pharmaceutical Contract Manufacturing Market in North America, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.96 Pharmaceutical Contract Manufacturing Market in the US, Historical Trends (2021-2024) and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.97 Pharmaceutical Contract Manufacturing Market in Canada, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.98 Pharmaceutical Contract Manufacturing Market in Europe, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.99 Pharmaceutical Contract Manufacturing Market in Germany, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.100 Pharmaceutical Contract Manufacturing Market in France, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.101 Pharmaceutical Contract Manufacturing Market in the UK, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.102 Pharmaceutical Contract Manufacturing Market in Italy, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.103 Pharmaceutical Contract Manufacturing Market in Spain, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.104 Pharmaceutical Contract Manufacturing Market in Rest of the Europe, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.105 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.106 Pharmaceutical Contract Manufacturing Market in China, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.107 Pharmaceutical Contract Manufacturing Market in Japan, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.108 Pharmaceutical Contract Manufacturing Market in India, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.109 Pharmaceutical Contract Manufacturing Market in South Korea, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.110 Pharmaceutical Contract Manufacturing Market in Australia, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.111 Pharmaceutical Contract Manufacturing Market in Rest of the Asia-Pacific, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.112 Pharmaceutical Contract Manufacturing Market in Latin America, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.113 Pharmaceutical Contract Manufacturing Market in Brazil, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.114 Pharmaceutical Contract Manufacturing Market in Argentina, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.115 Pharmaceutical Contract Manufacturing Market in Rest of the Latin America, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.116 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.117 Pharmaceutical Contract Manufacturing Market in Saudi Arabia, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.118 Pharmaceutical Contract Manufacturing Market in Egypt, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.119 Pharmaceutical Contract Manufacturing Market in Rest of the Middle East and North Africa, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Table 36.120 Pharmaceutical Contract Manufacturing Market: Distribution by Leading Players (USD Billion)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Market Assessment Framework
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Market Landscape
  • Figure 5.2 Executive Summary: Market Trends
  • Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 6.1 Type of Third-party Manufacturers
  • Figure 6.2 Outsourcing Opportunities in Pharmaceutical Value Chain
  • Figure 6.3 Services Offered by Contract Manufacturing Organizations
  • Figure 6.4 Key Considerations while Selecting a Contract Manufacturing Organization
  • Figure 7.1 Key Regulatory Requirements for CMOs and CROs in India
  • Figure 7.2 Regulatory Landscape for Pharmaceutical CMOs: Distribution by Type of Regulatory Authority
  • Figure 7.3 Bubble Analysis: Regional Regulatory Summary
  • Figure 8.1 Pharmaceutical Contract Manufacturing Organizations: Distribution by Year of Establishment
  • Figure 8.2 Pharmaceutical Contract Manufacturing Organizations: Distribution by Company Size
  • Figure 8.3 Pharmaceutical Contract Manufacturing Organizations: Distribution by Location of Headquarters (Region)
  • Figure 8.4 Pharmaceutical Contract Manufacturing Organizations: Distribution by Location of Headquarters (Country)
  • Figure 8.5 Pharmaceutical Contract Manufacturing Organizations: Distribution by Location of Manufacturing Facility (Region)
  • Figure 8.6 Pharmaceutical Contract Manufacturing Organizations: Distribution by Type of Offering
  • Figure 8.7 Pharmaceutical Contract Manufacturing Organizations: Distribution by Type of Pharmaceutical Product Manufactured
  • Figure 8.8 Pharmaceutical Contract Manufacturing Organizations: Distribution by Scale of Operation
  • Figure 8.9 Pharmaceutical Contract Manufacturing Organizations: Distribution by Type of Service Offered
  • Figure 8.10 Pharmaceutical Contract Manufacturing Organizations: Distribution by Type of Finished Dosage Form Manufactured
  • Figure 8.11 Pharmaceutical Contract Manufacturing Organizations: Distribution by Type of Packaging Offered
  • Figure 9.1 Albemarle: Business Segment-wise Financial Details (USD Billion), Since FY 2022
  • Figure 9.2 Thermo Fischer Scientific (Parent Company of Patheon): Consolidated Financial Details (USD Billion), Since FY 2022
  • Figure 9.3 West Pharmaceutical Services: Business Segment-wise Financial Details (USD Billion), Since FY 2022
  • Figure 9.4 Eurofins Scientific: Consolidated Financial Details (EUR Billion), Since FY 2022
  • Figure 9.5 Evonik Industries: Consolidated Financial Details (EUR Billion), Since FY 2022
  • Figure 9.6 Fresenius Kabi: Consolidated Financial Details (EUR Billion), Since FY 2022
  • Figure 9.7 Lonza: Business Segment-wise Financial Details (CHF Billion), Since FY 2022
  • Figure 9.8 Aspen Pharmacare: Consolidated Financial Details (CER Billion), Since FY 2022
  • Figure 9.9 WuXi AppTec: Consolidated Financial Details (RMB Billion), Since FY 2022
  • Figure 10.1 Make versus Buy Decision Making Framework
  • Figure 10.2 Make versus Buy Decision Making: Possible Scenario Descriptions
  • Figure 11.1 Mergers and Acquisitions: Distribution by Year of Agreement
  • Figure 11.2 Mergers and Acquisitions: Distribution by Type of Agreement
  • Figure 11.3 Mergers and Acquisitions: Distribution by Local and International Agreements
  • Figure 11.4 Mergers and Acquisitions: Distribution by Intracontinental and Intercontinental Agreements
  • Figure 11.5 Most Active Players: Distribution by Number of Agreements
  • Figure 11.6 Mergers and Acquisitions: Distribution by Ownership Change Matrix
  • Figure 11.7 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Figure 12.1 Recent Expansions: Distribution by Year of Expansion
  • Figure 12.2 Recent Expansions: Distribution by Status of Expansion
  • Figure 12.3 Recent Expansions: Distribution by Type of Expansion
  • Figure 12.4 Recent Expansions: Distribution by Year and Type of Expansion
  • Figure 12.5 Recent Expansions: Distribution by Location of Facility (Region)
  • Figure 12.6 Recent Expansions: Distribution by Location of Facility (Country)
  • Figure 12.7 Recent Expansions: Distribution by Distribution by Type of Expansion and Location of Facility (Region)
  • Figure 12.8 Recent Expansions: Distribution of Amount Invested by Year of Expansion
  • Figure 12.9 Recent Expansions: Distribution of Amount Invested by Type of Expansion
  • Figure 12.10 Recent Expansions: Distribution by Type of Pharmaceutical Product Manufactured
  • Figure 12.11 Recent Expansions: Distribution by Type of Service Offered
  • Figure 12.12 Most Active Players: Distribution by Number of Expansions
  • Figure 12.13 Most Active Players: Distribution by Amount Invested
  • Figure 13.1 Pharmaceutical Contract Manufacturing Organizations: Distribution by Location of Manufacturing Facilities
  • Figure 13.2 Pharmaceutical Contract Manufacturing Facilities: North America Scenario
  • Figure 13.3 Pharmaceutical Contract Manufacturing Facilities: Europe Scenario
  • Figure 13.4 Pharmaceutical Contract Manufacturing Facilities: Asia-Pacific Scenario
  • Figure 13.5 Pharmaceutical Contract Manufacturing Facilities: Rest of the World Scenario
  • Figure 14.1 Global Capacity of Pharmaceutical Contract Manufacturers (in million units): Distribution by Range of Installed Capacity
  • Figure 14.2 Global Capacity of Pharmaceutical Contract Manufacturers (in million units): Distribution by Company Size
  • Figure 14.3 Global Capacity of Pharmaceutical Contract Manufacturers (in million units): Distribution by Scale of Operation
  • Figure 14.4 Global Capacity of Pharmaceutical Contract Manufacturers (in million units): Distribution by Location of Manufacturing Facility
  • Figure 14.5 Pharmaceutical Contract Manufacturing Capacity in North America
  • Figure 14.6 Pharmaceutical Contract Manufacturing Capacity in Europe
  • Figure 14.7 Pharmaceutical Contract Manufacturing Capacity in Asia-Pacific
  • Figure 14.8 Pharmaceutical Contract Manufacturing Capacity in Rest of the World
  • Figure 15.1 Global Demand for Pharmaceutical Contract Manufacturing, Historical Trends, Since 2020 and Forecasted Estimates, Till 2035 (in Metric Tons)
  • Figure 15.2 Demand for Pharmaceutical Contract Manufacturing: Distribution by Scale of Operation, Historical Trends, Since 2020 and Forecasted Estimates, Till 2035 (in Metric Tons)
  • Figure 15.3 Demand for Pharmaceutical Contract Manufacturing: Distribution by Type of API, Historical Trends, Since 2020 and Forecasted Estimates, Till 2035 (in Metric Tons)
  • Figure 15.4 Demand for Pharmaceutical Contract Manufacturing: Distribution by Potency of API, Historical Trends, Since 2020 and Forecasted Estimates, Till 2035 (in Metric Tons)
  • Figure 15.5 Demand for Pharmaceutical Contract Manufacturing: Distribution by Geographical Regions, Historical Trends, Since 2020 and Forecasted Estimates, Till 2035 (in Metric Tons)
  • Figure 17.1 Global Pharmaceutical Contract Manufacturing Market, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 17.2 Global Pharmaceutical Contract Manufacturing Market, Forecasted Estimates, Till 2035: Conservative Scenario (USD Billion)
  • Figure 17.3 Global Pharmaceutical Contract Manufacturing Market, Forecasted Estimates, Till 2035: Optimistic Scenario (USD Billion)
  • Figure 18.1 Pharmaceutical Contract Manufacturing Market: Distribution by Type of Product Manufactured
  • Figure 18.2 Pharmaceutical Contract Manufacturing Market for API and Intermediates, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 18.3 Pharmaceutical Contract Manufacturing Market for FDFs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 19.1 Pharmaceutical Contract Manufacturing Market: Distribution by Type of API
  • Figure 19.2 Pharmaceutical Contract Manufacturing Market for Originator APIs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 19.3 Pharmaceutical Contract Manufacturing Market for Generic APIs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 20.1 Pharmaceutical Contract Manufacturing Market: Distribution by API Potency
  • Figure 20.2 Pharmaceutical Contract Manufacturing Market for Low Potent APIs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 20.3 Pharmaceutical Contract Manufacturing Market for High Potent APIs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 21.1 Pharmaceutical Contract Manufacturing Market: Distribution by Type of FDF
  • Figure 21.2 Pharmaceutical Contract Manufacturing Market for Originator FDFs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 21.3 Pharmaceutical Contract Manufacturing Market for Generic FDFs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 22.1 Pharmaceutical Contract Manufacturing Market: Distribution by Dosage Form
  • Figure 22.2 Pharmaceutical Contract Manufacturing Market for Oral Solids, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 22.3 Pharmaceutical Contract Manufacturing Market for Liquids, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 22.4 Pharmaceutical Contract Manufacturing Market for Emulsions, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 22.5 Pharmaceutical Contract Manufacturing Market for Other Dosage Forms, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 23.1 Pharmaceutical Contract Manufacturing Market: Distribution by Type of Oral Solid
  • Figure 23.2 Pharmaceutical Contract Manufacturing Market for Tablets, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 23.3 Pharmaceutical Contract Manufacturing Market for Capsules, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 23.4 Pharmaceutical Contract Manufacturing Market for Other Oral Solids, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 24.1 Pharmaceutical Contract Manufacturing Market: Distribution by Type of Packaging Offered
  • Figure 24.2 Pharmaceutical Contract Manufacturing Market for Bottles, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 24.3 Pharmaceutical Contract Manufacturing Market for Blister Packs, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 24.4 Pharmaceutical Contract Manufacturing Market for Oral Liquid Bottles, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 24.5 Pharmaceutical Contract Manufacturing Market for Vials, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 24.6 Pharmaceutical Contract Manufacturing Market for Prefilled Syringe, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 24.7 Pharmaceutical Contract Manufacturing Market for Cartridges, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 24.8 Pharmaceutical Contract Manufacturing Market for Ampoules, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 24.9 Pharmaceutical Contract Manufacturing Market for Other Types of Packaging, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 25.1 Pharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
  • Figure 25.2 Pharmaceutical Contract Manufacturing Market for Clinical Scale, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 25.3 Pharmaceutical Contract Manufacturing Market for Commercial Scale, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 26.1 Pharmaceutical Contract Manufacturing Market: Distribution by End User
  • Figure 26.2 Pharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 26.3 Pharmaceutical Contract Manufacturing Market for Mid-sized Companies, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 26.4 Pharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.1 Pharmaceutical Contract Manufacturing Market: Distribution by Geographical Region
  • Figure 27.2 Pharmaceutical Contract Manufacturing Market in North America, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.3 Pharmaceutical Contract Manufacturing Market in the US, Historical Trends (2021-2024) and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.4 Pharmaceutical Contract Manufacturing Market in Canada, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.5 Pharmaceutical Contract Manufacturing Market in Europe, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.6 Pharmaceutical Contract Manufacturing Market in Germany, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.7 Pharmaceutical Contract Manufacturing Market in France, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.8 Pharmaceutical Contract Manufacturing Market in the UK, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.9 Pharmaceutical Contract Manufacturing Market in Italy, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.10 Pharmaceutical Contract Manufacturing Market in Spain, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.11 Pharmaceutical Contract Manufacturing Market in Rest of the Europe, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.12 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.13 Pharmaceutical Contract Manufacturing Market in China, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.14 Pharmaceutical Contract Manufacturing Market in Japan, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.15 Pharmaceutical Contract Manufacturing Market in India, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.16 Pharmaceutical Contract Manufacturing Market in South Korea, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.17 Pharmaceutical Contract Manufacturing Market in Australia, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.18 Pharmaceutical Contract Manufacturing Market in Rest of the Asia-Pacific, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.19 Pharmaceutical Contract Manufacturing Market in Latin America, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.20 Pharmaceutical Contract Manufacturing Market in Brazil, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.21 Pharmaceutical Contract Manufacturing Market in Argentina, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.22 Pharmaceutical Contract Manufacturing Market in Rest of the Latin America, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.23 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.24 Pharmaceutical Contract Manufacturing Market in Saudi Arabia, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.25 Pharmaceutical Contract Manufacturing Market in Egypt, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.26 Pharmaceutical Contract Manufacturing Market in Rest of the Middle East and North Africa, Historical Trends, Since 2023 and Forecasted Estimates, Till 2035 (USD Billion)
  • Figure 27.27 Market Movement Analysis: Geographical Regions
  • Figure 27.28 Penetration-Growth (P-G) Matrix: Geographical Regions
  • Figure 28.1 Pharmaceutical Contract Manufacturing Market: Distribution by Leading Players (USD Billion)
  • Figure 33.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval
  • Figure 33.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
  • Figure 34.1 Conclusion: Market Landscape
  • Figure 34.2 Conclusion: Mergers and Acquisitions
  • Figure 34.3 Conclusion: Recent Expansions
  • Figure 34.4 Conclusion: Capacity Analysis
  • Figure 34.5 Conclusion: Demand Analysis
  • Figure 34.6 Conclusion: Market Sizing and Opportunity Analysis